Cofactors and metabolites as protein folding helpers in metabolic diseases

Current Topics in Medicinal Chemistry

Volumn 12, Issue 22, 2012, Pages 2546-2559

  Rodrigues, João V ^a   Henriques, Bárbara J ^a   Lucas, Tânia G ^a   Gomes, Cláudio M ^a  

^a INSTITUTO DE TECNOLOGIA QUÍMICA E BIOLÓGICA   (Portugal)

Author keywords

Fatty acid oxidation; Inborn errors of metabolism; Metabolites; Pharmacological chaperone; Riboflavin; Vitamin

Indexed keywords

ACYL COENZYME A DEHYDROGENASE; BIOTIN; CHAPERONE; CYANOCOBALAMIN; CYSTATHIONINE; ELECTRON TRANSFERRING FLAVOPROTEIN; G PROTEIN COUPLED RECEPTOR; LIGAND; PYRIDOXINE; RIBOFLAVIN; TETRAHYDROBIOPTERIN; VITAMIN;

CRYSTAL STRUCTURE; FATTY ACID OXIDATION; FLUOROMETRY; GAUCHER DISEASE; GENE EXPRESSION; GENETIC DISORDER; HUMAN; INBORN ERROR OF METABOLISM; METABOLIC DISORDER; METABOLITE; MISSENSE MUTATION; MITOCHONDRION; PHENYLKETONURIA; POINT MUTATION; PROTEIN FOLDING; PROTEIN FUNCTION; REVIEW; VITAMIN SUPPLEMENTATION;

FATTY ACIDS; HUMANS; LIGANDS; METABOLIC DISEASES; MOLECULAR TARGETED THERAPY; OXIDATION-REDUCTION; PHENYLKETONURIAS; PROTEIN FOLDING; RIBOFLAVIN; VITAMINS;

EID: 84874923658     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026611212220009     Document Type: Review

References (101)

1. Balch, W. E.; Morimoto, R. I.; Dillin, A.; Kelly, J. W., Adapting proteostasis for disease intervention. Science, 2008, 319 (5865), 916-919.
2. Leandro, P.; Gomes, C. M., Protein misfolding in conformational disorders: rescue of folding defects and chemical chaperoning. Mini Rev Med Chem, 2008, 8 (9), 901-911.
3. Henriques, B. J.; Olsen, R. K.; Bross, P.; Gomes, C. M., Emerging roles for riboflavin in functional rescue of mitochondrial beta-oxidation flavoenzymes. Curr Med Chem, 2010, 17 (32), 3842-3854.
4. Fan, J. Q., A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity. Trends Pharmacol Sci, 2003, 24 (7), 355-360.
5. Fan, J. Q.; Ishii, S., Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors. FEBS J, 2007, 274 (19), 4962-4971.
6. Fan, J. Q.; Ishii, S.; Asano, N.; Suzuki, Y., Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat Med, 1999, 5 (1), 112-115.
7. Sawkar, A. R.; Cheng, W. C.; Beutler, E.; Wong, C. H.; Balch, W. E.; Kelly, J. W., Chemical chaperones increase the cellular activity of N370S beta -glucosidase: a therapeutic strategy for Gaucher disease. Proc Natl Acad Sci U S A, 2002, 99 (24), 15428-15433.
8. Yu, Z.; Sawkar, A. R.; Kelly, J. W., Pharmacologic chaperoning as a strategy to treat Gaucher disease. FEBS J, 2007, 274 (19), 4944-4950.
9. Sawkar, A. R.; D'Haeze, W.; Kelly, J. W., Therapeutic strategies to ameliorate lysosomal storage disorders--a focus on Gaucher disease. Cell Mol Life Sci, 2006, 63 (10), 1179-1192.
10. Shanmuganathan, M.; Britz-McKibbin, P., Inhibitor screening of pharmacological chaperones for lysosomal beta-glucocerebrosidase by capillary electrophoresis. Anal Bioanal Chem, 2011, 399 (8), 2843-2853.
11. Zheng, W.; Padia, J.; Urban, D. J.; Jadhav, A.; Goker-Alpan, O.; Simeonov, A.; Goldin, E.; Auld, D.; LaMarca, M. E.; Inglese, J.; Austin, C. P.; Sidransky, E., Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease. Proc Natl Acad Sci U S A, 2007, 104 (32), 13192-13197.
12. Alfonso, P.; Pampin, S.; Estrada, J.; Rodriguez-Rey, J. C.; Giraldo, P.; Sancho, J.; Pocovi, M., Miglustat (NB-DNJ) works as a chaperone for mutated acid beta-glucosidase in cells transfected with several Gaucher disease mutations. Blood Cells Mol Dis, 2005, 35 (2), 268-276.
13. Okumiya, T.; Kroos, M. A.; Vliet, L. V.; Takeuchi, H.; Van der Ploeg, A. T.; Reuser, A. J., Chemical chaperones improve transport and enhance stability of mutant alpha-glucosidases in glycogen storage disease type II. Mol Genet Metab, 2007, 90 (1), 49-57.
14. Parenti, G.; Zuppaldi, A.; Gabriela Pittis, M.; Rosaria Tuzzi, M.; Annunziata, I.; Meroni, G.; Porto, C.; Donaudy, F.; Rossi, B.; Rossi, M.; Filocamo, M.; Donati, A.; Bembi, B.; Ballabio, A.; Andria, G., Pharmacological enhancement of mutated alpha-glucosidase activity in fibroblasts from patients with Pompe disease. Mol Ther, 2007, 15 (3), 508-514.
15. Flanagan, J. J.; Rossi, B.; Tang, K.; Wu, X.; Mascioli, K.; Donaudy, F.; Tuzzi, M. R.; Fontana, F.; Cubellis, M. V.; Porto, C.; Benjamin, E.; Lockhart, D. J.; Valenzano, K. J.; Andria, G.; Parenti, G.; Do, H. V., The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha-glucosidase. Hum Mutat, 2009, 30 (12), 1683-1692.
16. Rountree, J. S.; Butters, T. D.; Wormald, M. R.; Boomkamp, S. D.; Dwek, R. A.; Asano, N.; Ikeda, K.; Evinson, E. L.; Nash, R. J.; Fleet, G. W., Design, synthesis, and biological evaluation of enantiomeric beta-N-acetylhexosaminidase inhibitors LABNAc and DABNAc as potential agents against Tay-Sachs and Sandhoff disease. Chem Med Chem, 2009, 4 (3), 378-392.
17. Conn, P. M.; Ulloa-Aguirre, A.; Ito, J.; Janovick, J. A., G protein-coupled receptor trafficking in health and disease: lessons learned to prepare for therapeutic mutant rescue in vivo. Pharmacol Rev, 2007, 59 (3), 225-250.
18. Morello, J. P.; Salahpour, A.; Laperriere, A.; Bernier, V.; Arthus, M. F.; Lonergan, M.; Petaja-Repo, U.; Angers, S.; Morin, D.; Bichet, D. G.; Bouvier, M., Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J Clin Invest, 2000, 105 (7), 887-895.
19. Conn, P. M.; Janovick, J. A., Trafficking and quality control of the gonadotropin releasing hormone receptor in health and disease. Mol Cell Endocrinol, 2009, 299 (2), 137-145.
20. Clayton, P. T., B6-responsive disorders: a model of vitamin dependency. J Inherit Metab Dis, 2006, 29 (2-3), 317-326.
21. Rabbani, B.; Mahdieh, N.; Hosomichi, K.; Nakaoka, H.; Inoue, I., Next-generation sequencing: impact of exome sequencing in characterizing Mendelian disorders. J Hum Genet, 2012 doi: 10.1038/jhg., 2012.91.
22. Erlandsen, H.; Pey, A. L.; Gamez, A.; Perez, B.; Desviat, L. R.; Aguado, C.; Koch, R.; Surendran, S.; Tyring, S.; Matalon, R.; Scriver, C. R.; Ugarte, M.; Martinez, A.; Stevens, R. C., Correction of kinetic and stability defects by tetrahydrobiopterin in phenylketonuria patients with certain phenylalanine hydroxylase mutations. Proc Natl Acad Sci U S A, 2004, 101 (48), 16903-16908.
23. Perez, B.; Desviat, L. R.; Gomez-Puertas, P.; Martinez, A.; Stevens, R. C.; Ugarte, M., Kinetic and stability analysis of PKU mutations identified in BH4-responsive patients. Mol Genet Metab, 2005, 86 Suppl 1, S11-S16.
24. Alves, E.; Henriques, B. J.; Rodrigues, J. V.; Prudencio, P.; Rocha, H.; Vilarinho, L.; Martinho, R. G.; Gomes, C. M., Mutations at the flavin binding site of ETF:QO yield a MADD-like severe phenotype in Drosophila. Biochim Biophys Acta, 2012, 1822 (8), 1284-1292.
25. Mayfield, J. A.; Davies, M. W.; Dimster-Denk, D.; Pleskac, N.; McCarthy, S.; Boydston, E. A.; Fink, L.; Lin, X. X.; Narain, A. S.; Meighan, M.; Rine, J., Surrogate genetics and metabolic profiling for characterization of human disease alleles. Genetics, 2012, 190 (4), 1309-1323.
26. Henriques, B. J.; Rodrigues, J. V.; Gomes, C. M., Riboflavin and Beta-oxidation Flavoenzymes. In B Vitamins and Folate: Chemistry, Analysis, Function and Effects, Preedy, V. R., Ed. Royal Society of Chemistry:, 2013; pp 611-632.
27. Hoppel, C.; DiMarco, J. P.; Tandler, B., Riboflavin and rat hepatic cell structure and function. Mitochondrial oxidative metabolism in deficiency states. The Journal of biological chemistry, 1979, 254 (10), 4164-4170.
28. Ross, N. S.; Hansen, T. P., Riboflavin deficiency is associated with selective preservation of critical flavoenzyme-dependent metabolic pathways. Biofactors, 1992, 3 (3), 185-190.
29. Gianazza, E.; Vergani, L.; Wait, R.; Brizio, C.; Brambilla, D.; Begum, S.; Giancaspero, T. A.; Conserva, F.; Eberini, I.; Bufano, D.; Angelini, C.; Pegoraro, E.; Tramontano, A.; Barile, M., Coordinated and reversible reduction of enzymes involved in terminal oxidative metabolism in skeletal muscle mitochondria from a riboflavin-responsive, multiple acyl-CoA dehydrogenase deficiency patient. Electrophoresis, 2006, 27 (5-6), 1182-1198.
30. Bartlett, K.; Eaton, S., Mitochondrial beta-oxidation. European journal of biochemistry / FEBS, 2004, 271 (3), 462-469.
31. de Lonlay, P.; Giurgea, I.; Touati, G.; Saudubray, J. M., Neonatal hypoglycaemia: aetiologies. Semin Neonatol, 2004, 9 (1), 49-58.
32. Sakurai, T.; Miyazawa, S.; Furuta, S.; Hashimoto, T., Riboflavin deficiency and beta-oxidation systems in rat liver. Lipids, 1982, 17 (9), 598-604.
33. Veitch, K.; Draye, J. P.; Vamecq, J.; Causey, A. G.; Bartlett, K.; Sherratt, H. S.; Van, H. F., Altered acyl-CoA metabolism in riboflavin deficiency. Biochim. Biophys. Acta, 1989, 1006 (3), 335-343.
34. Gregersen, N.; Wintzensen, H.; Christensen, S. K.; Christensen, M. F.; Brandt, N. J.; Rasmussen, K., C6-C10-dicarboxylic aciduria: investigations of a patient with riboflavin responsive multiple acyl-CoA dehydrogenation defects. Pediatr Res, 1982, 16 (10), 861-868.
35. Bernsen, P. L.; Gabreels, F. J.; Ruitenbeek, W.; Sengers, R. C.; Stadhouders, A. M.; Renier, W. O., Successful treatment of pure myopathy, associated with complex I deficiency, with riboflavin and carnitine. Archives of neurology, 1991, 48 (3), 334-338.
36. Bernsen, P. L.; Gabreels, F. J.; Ruitenbeek, W.; Hamburger, H. L., Treatment of complex I deficiency with riboflavin. Journal of the neurological sciences, 1993, 118 (2), 181-187.
37. Griebel, V.; Krageloh-Mann, I.; Ruitenbeek, W.; Trijbels, J. M.; Paulus, W., A mitochondrial myopathy in an infant with lactic acidosis. Developmental medicine and child neurology, 1990, 32 (6), 528-531.
38. Bugiani, M.; Lamantea, E.; Invernizzi, F.; Moroni, I.; Bizzi, A.; Zeviani, M.; Uziel, G., Effects of riboflavin in children with complex II deficiency. Brain & development, 2006, 28 (9), 576-581.
39. Pinard, J. M.; Marsac, C.; Barkaoui, E.; Desguerre, I.; Birch-Machin, M.; Reinert, P.; Ponsot, G., [Leigh syndrome and leukodystrophy due to partial succinate dehydrogenase deficiency: regression with riboflavin]. Arch Pediatr, 1999, 6 (4), 421-426.
40. Duran, M.; Cleutjens, C. B.; Ketting, D.; Dorland, L.; de Klerk, J. B.; van Sprang, F. J.; Berger, R., Diagnosis of medium-chain acyl-CoA dehydrogenase deficiency in lymphocytes and liver by a gas chromatographic method: the effect of oral riboflavin supplementation. Pediatr Res, 1992, 31 (1), 39-42.
41. van Maldegem, B. T.; Duran, M.; Wanders, R. J.; Waterham, H. R.; Wijburg, F. A., Flavin adenine dinucleotide status and the effects of high-dose riboflavin treatment in short-chain acyl-CoA dehydrogenase deficiency. Pediatr. Res., 2010, 67 (3), 304-308.
42. Corydon, M. J.; Gregersen, N.; Lehnert, W.; Ribes, A.; Rinaldo, P.; Kmoch, S.; Christensen, E.; Kristensen, T. J.; Andresen, B. S.; Bross, P.; Winter, V.; Martinez, G.; Neve, S.; Jensen, T. G.; Bolund, L.; Kolvraa, S., Ethylmalonic aciduria is associated with an amino acid variant of short chain acyl-coenzyme A dehydrogenase. Pediatr. Res., 1996, 39 (6), 1059-1066.
43. Nagan, N.; Kruckeberg, K. E.; Tauscher, A. L.; Bailey, K. S.; Rinaldo, P.; Matern, D., The frequency of short-chain acyl-CoA dehydrogenase gene variants in the US population and correlation with the C(4)-acylcarnitine concentration in newborn blood spots. Mol. Genet. Metab, 2003, 78 (4), 239-246.
44. Gregersen, N.; Andresen, B. S.; Pedersen, C. B.; Olsen, R. K.; Corydon, T. J.; Bross, P., Mitochondrial fatty acid oxidation defects--remaining challenges. J. Inherit. Metab Dis., 2008, 31 (5), 643-657.
45. Pedersen, C. B.; Bross, P.; Winter, V. S.; Corydon, T. J.; Bolund, L.; Bartlett, K.; Vockley, J.; Gregersen, N., Misfolding, degradation, and aggregation of variant proteins. The molecular pathogenesis of short chain acyl-CoA dehydrogenase (SCAD) deficiency. The Journal of biological chemistry, 2003, 278 (48), 47449-47458.
46. Kmoch, S.; Zeman, J.; Hrebicek, M.; Ryba, L.; Kristensen, M. J.; Gregersen, N., Riboflavin-responsive epilepsy in a patient with SER209 variant form of short-chain acyl-CoA dehydrogenase. J Inherit Metab Dis, 1995, 18 (2), 227-229.
47. Stenson, P. D.; Ball, E. V.; Howells, K.; Phillips, A. D.; Mort, M.; Cooper, D. N., The Human Gene Mutation Database: providing a comprehensive central mutation database for molecular diagnostics and personalized genomics. Hum Genomics, 2009, 4 (2), 69-72.
48. al-Essa, M. A.; Rashed, M. S.; Bakheet, S. M.; Patay, Z. J.; Ozand, P. T., Glutaric aciduria type II: observations in seven patients with neonatal- and late-onset disease. J Perinatol, 2000, 20 (2), 120-128.
49. Frerman, F. E., Goodman, S. I., Scriver, C. R., Beaudet, A. L., Sly, W. S., Valle, D., Childs, B., Kinzler, K. W., and Vogelstein, B., Defects of Electron Transfer Flavoprotein and Electron Transfer Flavoprotein-Ubiquinone Oxidoreductase: Glutaric Acidemia Type II. In The Metabolic & Molecular Basis of Inherited Disease McGrawHill: New York, 2001; pp 2357-2365.
50. Schiff, M.; Froissart, R.; Olsen, R. K.; Acquaviva, C.; Vianey- Saban, C., Electron transfer flavoprotein deficiency: functional and molecular aspects. Mol Genet Metab, 2006, 88 (2), 153-158.
51. Olsen, R. K.; Olpin, S. E.; Andresen, B. S.; Miedzybrodzka, Z. H.; Pourfarzam, M.; Merinero, B.; Frerman, F. E.; Beresford, M. W.; Dean, J. C.; Cornelius, N.; Andersen, O.; Oldfors, A.; Holme, E.; Gregersen, N.; Turnbull, D. M.; Morris, A. A., ETFDH mutations as a major cause of riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency. Brain, 2007, 130 (Pt 8), 2045-2054.
52. Gempel, K.; Topaloglu, H.; Talim, B.; Schneiderat, P.; Schoser, B. G.; Hans, V. H.; Palmafy, B.; Kale, G.; Tokatli, A.; Quinzii, C.; Hirano, M.; Naini, A.; DiMauro, S.; Prokisch, H.; Lochmuller, H.; Horvath, R., The myopathic form of coenzyme Q10 deficiency is caused by mutations in the electron-transferring-flavoprotein dehydrogenase (ETFDH) gene. Brain, 2007, 130 (Pt 8), 2037-2044.
53. Wen, B.; Dai, T.; Li, W.; Zhao, Y.; Liu, S.; Zhang, C.; Li, H.; Wu, J.; Li, D.; Yan, C., Riboflavin-responsive lipid-storage myopathy caused by ETFDH gene mutations. Journal of neurology, neurosurgery, and psychiatry, 2010, 81 (2), 231-236.
54. Law, L. K.; Tang, N. L.; Hui, J.; Fung, S. L.; Ruiter, J.; Wanders, R. J.; Fok, T. F.; Lam, C. W., Novel mutations in ETFDH gene in Chinese patients with riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency. Clin.Chim.Acta, 2009, 404 (2), 95-99.
55. Liang, W. C.; Ohkuma, A.; Hayashi, Y. K.; Lopez, L. C.; Hirano, M.; Nonaka, I.; Noguchi, S.; Chen, L. H.; Jong, Y. J.; Nishino, I., ETFDH mutations, CoQ10 levels, and respiratory chain activities in patients with riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency. Neuromuscul. Disord., 2009, 19 (3), 212-216.
56. Lan, M. Y.; Fu, M. H.; Liu, Y. F.; Huang, C. C.; Chang, Y. Y.; Liu, J. S.; Peng, C. H.; Chen, S. S., High frequency of ETFDH c.250G>A mutation in Taiwanese patients with late-onset lipid storage myopathy. Clin Genet, 2010, 78 (6), 565-569.
57. Lammer, A. B.; Rolinski, B.; Ahting, U.; Heuss, D., Multiple acyl-CoA-dehydrogenase deficiency (MADD)--a novel mutation of electron-transferring-flavoprotein dehydrogenase ETFDH. Journal of the neurological sciences, 2011, 307 (1-2), 166-167.
58. Wang, Z. Q.; Chen, X. J.; Murong, S. X.; Wang, N.; Wu, Z. Y., Molecular analysis of 51 unrelated pedigrees with late-onset multiple acyl-CoA dehydrogenation deficiency (MADD) in southern China confirmed the most common ETFDH mutation and high carrier frequency of c.250G>A. J Mol Med (Berl), 2011, 89 (6), 569-576.
59. Zhang, J.; Frerman, F. E.; Kim, J. J., Structure of electron transfer flavoprotein-ubiquinone oxidoreductase and electron transfer to the mitochondrial ubiquinone pool. Proc Natl Acad Sci U S A, 2006, 103 (44), 16212-16217.
60. Laskowski, R. A.; Hutchinson, E. G.; Michie, A. D.; Wallace, A. C.; Jones, M. L.; Thornton, J. M., PDBsum: a Web-based database of summaries and analyses of all PDB structures. Trends Biochem Sci, 1997, 22 (12), 488-490.
61. Cornelius, N.; Frerman, F. E.; Corydon, T. J.; Palmfeldt, J.; Bross, P.; Gregersen, N.; Olsen, R. K., Molecular mechanisms of riboflavin responsiveness in patients with ETF-QO variations and multiple acyl-CoA dehydrogenation deficiency. Hum Mol Genet, 2012, 21 (15), 3435-3448.
62. Rodrigues, J. V.; Gomes, C. M., Mechanism of superoxide and hydrogen peroxide generation by human electron-transfer flavoprotein and pathological variants. Free radical biology & medicine, 2012, 53 (1), 12-19.
63. Nagao, M.; Tanaka, K., FAD-dependent regulation of transcription, translation, post-translational processing, and post-processing stability of various mitochondrial acyl-CoA dehydrogenases and of electron transfer flavoprotein and the site of holoenzyme formation. The Journal of biological chemistry, 1992, 267 (25), 17925-17932.
64. Saijo, T.; Tanaka, K., Isoalloxazine ring of FAD is required for the formation of the core in the Hsp60-assisted folding of medium chain acyl-CoA dehydrogenase subunit into the assembly competent conformation in mitochondria. The Journal of biological chemistry, 1995, 270 (4), 1899-1907.
65. Sato, K.; Nishina, Y.; Shiga, K., In vitro refolding and unfolding of subunits of electron-transferring flavoprotein: characterization of the folding intermediates and the effects of FAD and AMP on the folding reaction. J Biochem (Tokyo), 1996, 120 (2), 276-285.
66. Windmueller, H. G.; Anderson, A. A.; Mickelsen, O., Elevated Riboflavin Levels in Urine of Fasting Human Subjects. Am J Clin Nutr, 1964, 15, 73-76.
67. Manore, M. M., Effect of physical activity on thiamine, riboflavin, and vitamin B-6 requirements. Am J Clin Nutr, 2000, 72 (2 Suppl), 598S-606S.
68. Lakshmi, A. V., Riboflavin metabolism--relevance to human nutrition. Indian J Med Res, 1998, 108, 182-190.
69. Powers, H. J., Riboflavin (vitamin B-2) and health. Am J Clin Nutr, 2003, 77 (6), 1352-1360.
70. Henriques, B. J.; Rodrigues, J. V.; Olsen, R. K.; Bross, P.; Gomes, C. M., Role of flavinylation in a mild variant of multiple acyl-CoA dehydrogenation deficiency: a molecular rationale for the effects of riboflavin supplementation. The Journal of biological chemistry, 2009, 284 (7), 4222-4229.
71. Olsen, R. K.; Andresen, B. S.; Christensen, E.; Bross, P.; Skovby, F.; Gregersen, N., Clear relationship between ETF/ETFDH genotype and phenotype in patients with multiple acyl-CoA dehydrogenation deficiency. Hum Mutat, 2003, 22 (1), 12-23.
72. Henriques, B. J.; Bross, P.; Gomes, C. M., Mutational hotspots in electron transfer flavoprotein underlie defective folding and function in multiple acyl-CoA dehydrogenase deficiency. Biochim Biophys Acta, 2010, 1802 (11), 1070-1077.
73. Lucas, T. G.; Henriques, B. J.; Rodrigues, J. V.; Bross, P.; Gregersen, N.; Gomes, C. M., Cofactors and metabolites as potential stabilizers of mitochondrial acyl-CoA dehydrogenases. Biochim Biophys Acta, 2011, 1812 (12), 1658-1663.
74. http://www.biopku.org (accessed 3 June 2012)
75. http://cbs.lf1.cuni.cz/cbsdata/cbsmain.htm (accessed 10 June 2012)
76. Feldman, G. L.; Hsia, Y. E.; Wolf, B., Biochemical characterization of biotin-responsive multiple carboxylase deficiency: heterogeneity within the bio genetic complementation group. Am J Hum Genet, 1981, 33 (5), 692-701.
77. Erlandsen, H.; Pey, A. L.; Gamez, A.; Perez, B.; Desviat, L. R.; Aguado, C.; Koch, R.; Surendran, S.; Tyring, S.; Matalon, R.; Scriver, C. R.; Ugarte, M.; Martinez, A.; Stevens, R. C., Correction of kinetic and stability defects by tetrahydrobiopterin in phenylketonuria patients with certain phenylalanine hydroxylase mutations. Proc Natl Acad Sci U S A, 2004, 101 (48), 16903-16908.
78. Pey, A. L.; Perez, B.; Desviat, L. R.; Martinez, M. A.; Aguado, C.; Erlandsen, H.; Gamez, A.; Stevens, R. C.; Thorolfsson, M.; Ugarte, M.; Martinez, A., Mechanisms underlying responsiveness to tetrahydrobiopterin in mild phenylketonuria mutations. Hum Mutat, 2004, 24 (5), 388-399.
79. Dobrowolski, S. F.; Pey, A. L.; Koch, R.; Levy, H.; Ellingson, C. C.; Naylor, E. W.; Martinez, A., Biochemical characterization of mutant phenylalanine hydroxylase enzymes and correlation with clinical presentation in hyperphenylalaninaemic patients. J Inherit Metab Dis, 2009, 32 (1), 10-21.
80. Cerreto, M.; Cavaliere, P.; Carluccio, C.; Amato, F.; Zagari, A.; Daniele, A.; Salvatore, F., Natural phenylalanine hydroxylase variants that confer a mild phenotype affect the enzyme's conformational stability and oligomerization equilibrium. Biochim Biophys Acta, 2011, 1812 (11), 1435-1445.
81. Thony, B.; Calvo, A. C.; Scherer, T.; Svebak, R. M.; Haavik, J.; Blau, N.; Martinez, A., Tetrahydrobiopterin shows chaperone activity for tyrosine hydroxylase. J Neurochem, 2008, 106 (2), 672-681.
82. Willard, H. F.; Rosenberg, L. E., Inherited methylmalonyl CoA mutase apoenzyme deficiency in human fibroblasts: evidence for allelic heterogeneity, genetic compounds, and codominant expression. J Clin Invest, 1980, 65 (3), 690-698.
83. Froese, D. S.; Healy, S.; McDonald, M.; Kochan, G.; Oppermann, U.; Niesen, F. H.; Gravel, R. A., Thermolability of mutant MMACHC protein in the vitamin B12-responsive cblC disorder. Mol Genet Metab, 2010, 100 (1), 29-36.
84. Kim, Y. J.; Rosenberg, L. E., On the mechanism of pyridoxine responsive homocystinuria. II. Properties of normal and mutant cystathionine beta-synthase from cultured fibroblasts. Proc Natl Acad Sci U S A, 1974, 71 (12), 4821-4825.
85. Fowler, B.; Kraus, J.; Packman, S.; Rosenberg, L. E., Homocystinuria. Evidence for three distinct classes of cystathionine beta-synthase mutants in cultured fibroblasts. J Clin Invest, 1978, 61 (3), 645-653.
86. Coulter-Mackie, M. B.; Lian, Q., Partial trypsin digestion as an indicator of mis-folding of mutant alanine:glyoxylate aminotransferase and chaperone effects of specific ligands. Study of a spectrum of missense mutants. Mol Genet Metab, 2008, 94 (3), 368-374.
87. Cellini, B.; Montioli, R.; Paiardini, A.; Lorenzetto, A.; Voltattorni, C. B., Molecular Insight into the Synergism between the Minor Allele of Human Liver Peroxisomal Alanine:Glyoxylate Aminotransferase and the F152I Mutation. The Journal of biological chemistry, 2009, 284 (13), 8349-58.
88. Kennaway, N. G.; Stankova, L.; Wirtz, M. K.; Weleber, R. G., Gyrate atrophy of the choroid and retina: characterization of mutant ornithine aminotransferase and mechanism of response to vitamin B6. Am J Hum Genet, 1989, 44 (3), 344-352.
89. Cotter, P. D.; May, A.; Fitzsimons, E. J.; Houston, T.; Woodcock, B. E.; al-Sabah, A. I.; Wong, L.; Bishop, D. F., Late-onset X-linked sideroblastic anemia. Missense mutations in the erythroid deltaaminolevulinate synthase (ALAS2) gene in two pyridoxineresponsive patients initially diagnosed with acquired refractory anemia and ringed sideroblasts. J Clin Invest, 1995, 96 (4), 2090-2096.
90. Perry, C.; Yu, S.; Chen, J.; Matharu, K. S.; Stover, P. J., Effect of vitamin B6 availability on serine hydroxymethyltransferase in MCF-7 cells. Arch Biochem Biophys, 2007, 462 (1), 21-27.
91. Brahatheeswaran, B.; Prakash, V.; Savithri, H. S.; Rao, N. A., Interaction of sheep liver apo-serine hydroxymethyltransferase with pyridoxal-5'-phosphate: a physicochemical, kinetic, and thermodynamic study. Arch Biochem Biophys, 1996, 330 (2), 363-372.
92. Matsuda, N.; Hayashi, H.; Miyatake, S.; Kuroiwa, T.; Kagamiyama, H., Instability of the apo form of aromatic L-amino acid decarboxylase in vivo and in vitro: implications for the involvement of the flexible loop that covers the active site. J Biochem, 2004, 135 (1), 33-42.
93. Giardina, G.; Montioli, R.; Gianni, S.; Cellini, B.; Paiardini, A.; Voltattorni, C. B.; Cutruzzola, F., Open conformation of human DOPA decarboxylase reveals the mechanism of PLP addition to Group II decarboxylases. Proc Natl Acad Sci U S A, 2011, 108 (51), 20514-20519.
94. Chen, C. H.; Wu, S. J.; Martin, D. L., Structural characteristics of brain glutamate decarboxylase in relation to its interaction and activation. Arch Biochem Biophys, 1998, 349 (1), 175-182.
95. Gross-Mesilaty, S.; Hargrove, J. L.; Ciechanover, A., Degradation of tyrosine aminotransferase (TAT) via the ubiquitin-proteasome pathway. FEBS Lett, 1997, 405 (2), 175-180.
96. Saijo, T.; Tanaka, K., Isoalloxazine ring of FAD is required for the formation of the core in the Hsp60-assisted folding of medium chain acyl-CoA dehydrogenase subunit into the assembly competent conformation in mitochondria. The Journal of biological chemistry, 1995, 270 (4), 1899-1907.
97. Lucas, T. G.; Henriques, B. J.; Rodrigues, J. V.; Bross, P.; Gregersen, N.; Gomes, C. M., Cofactors and metabolites as potential stabilizers of mitochondrial acyl-CoA dehydrogenases. Biochim Biophys Acta, 2011, 1812 (12), 1658-1663.
98. Henriques, B. J.; Rodrigues, J. V.; Olsen, R. K.; Bross, P.; Gomes, C. M., Role of flavinylation in a mild variant of multiple acyl-CoA dehydrogenation deficiency: a molecular rationale for the effects of riboflavin supplementation. The Journal of biological chemistry, 2009, 284 (7), 4222-4229.
99. Cornelius, N.; Frerman, F. E.; Corydon, T. J.; Palmfeldt, J.; Bross, P.; Gregersen, N.; Olsen, R. K., Molecular mechanisms of riboflavin responsiveness in patients with ETF-QO variations and multiple acyl-CoA dehydrogenation deficiency. Hum Mol Genet, 2012, 21 (15), 3435-3448.
100. Xia, C.; Panda, S. P.; Marohnic, C. C.; Martasek, P.; Masters, B. S.; Kim, J. J., Structural basis for human NADPH-cytochrome P450 oxidoreductase deficiency. Proc Natl Acad Sci U S A, 2011, 108 (33), 13486-13491.
101. Yamada, K.; Chen, Z.; Rozen, R.; Matthews, R. G., Effects of common polymorphisms on the properties of recombinant human methylenetetrahydrofolate reductase. Proc Natl Acad Sci U S A, 2001, 98 (26), 14853-14858.